References
- Kibbler CC, Seaton S, Barnes RA, et al. Management and outcome of bloodstream infections due to Candida species in England and Wales. J Hosp Infect 2003; 54: 18–24
- National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Approved Standard M27-A2, 2nd edn. NCCLS, VillanovaPA, USA, 2002.
- Wingard JR, Merz WG, Rinaldi MG, et al. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991; 325: 1274–1277
- Hoy, JF. Flucytosine. In:. A Kucers, Crowe, SM, Grayson, ML, Hoy, JF, editors. The Use of Antibiotics. 5th edn. pp, 1304–1316.
- Pfaller MA, Messer SA, Boyken L, et al. In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods. Antimicrob Agents Chemother 2002; 46: 3518–3521
- Pfaller MA, Messer SA, Boyken L, et al. Caspofungin activity against clinical isolates of fluconazole-resistant Candida. J Clin Microbiol 2003; 41: 5729–5731
- Mora-Duarte J, Betts R, Rotstein C, et al. Caspofungin Invasive Candidiasis Study Group. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020–2029
- Canton E, Peman J, Gobernado M, Viudes A, Espinel-Ingroff A. Patterns of amphotericin B killing kinetics against seven Candida species. Antimicrob Agents Chemother 2004; 48: 2477–2482
- Nivoix Y, Zamfir A, Lutun P, et al. Combination of caspofungin and an azole or an amphotericin B formulation in invasive fungal infections. J Infect 2006; 52: 67–74
- Sora F, Chiusolo P, Piccirillo N, et al. Successful treatment with caspofungin of hepatosplenic candidiasis resistant to liposomal amphotericin B. Clin Infect Dis 2002; 35: 1135
- McGee WT, Tereso GJ. Successful treatment of Candida krusei infection with caspofungin acetate: a new antifungal agent. Crit Care Med 2003; 31: 1577–1578
- Hossain MA, Reyes GH, Long LA, Mukherjee PK, Ghannoum MA. Efficacy of caspofungin combined with amphotericin B against azole-resistant Candida albicans. J Antimicrob Chemother 2003; 51: 1427–1429
- Flattery, AM, Bartizal, K, Gill, CJ, , et al. Preclinical efficacy of MK-991 in combination with amphotericin B or fluconazole in mouse models of disseminated aspergillosis, candidiasis and cryptococcosis. In. Program and Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 1998. Abstract J-61, p., 468. American Society for Microbiology, Washington DCUSA.
- Pelletier R, Alarie I, Lagace R, Walsh TJ. Emergence of disseminated candidiasis caused by Candida krusei during treatment with caspofungin: case report and review of literature. Med Mycol 2005; 43: 559–564